- SUBSTITUTED GUANIDINE COMPOUND
-
The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
- -
-
Paragraph 0259; 0260
(2019/11/14)
-
- SUBSTITUTED GUANIDINE DERIVATIVE
-
The present invention provides a compound of general formula (I) (wherein, R1, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
- -
-
Paragraph 1211; 1212
(2018/06/23)
-
- Nitrogen-containing, fluoroalkyl sulfonyl chloride method for the preparation of (by machine translation)
-
The invention discloses a nitrogen-containing, fluoroalkyl sulfonyl chloride method for preparing, by containing nitrogen/perfluoroalkyl alcohol as the raw material, under the alkaline condition and a sulfonyl chloride the reaction produces the corresponding nitrogen-containing/perfluoroalkyl sulfonate ester, then nitrogen-containing/perfluoroalkyl sulfonate ester with a thio acetic acid potassium generating affinity substitution reaction to produce the nitrogen-containing/Fluoalkyl thiophosphoro acetate, then the chlorine treatment to obtain nitrogen-containing/fluoroalkyl sulfonyl chloride. The synthesis of this invention containing nitrogen (fluoro) alkyl sulfonyl chloride, the compound is a drug, pesticide research and development and production of important pharmaceutical intermediate, the compound of preparation of the alkyl sulfonyl chloride synthesis of pharmaceutical intermediates database, to the market to provide alkyl sulfonyl chloride can be synthetic fragment. Raw materials used in the present invention chemical reagent is commercially available, low cost, short synthetic route, high yield, high product purity chemical, provides high-purity products, so as to obtain higher economic benefits. (by machine translation)
- -
-
Paragraph 0023; 0033; 0034
(2016/10/10)
-
- SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS
-
The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
- -
-
Paragraph 0651; 0652
(2016/01/15)
-
- IMAGING NEURAL ACTIVITY
-
The present invention provides a novel radiofluorinated compound for imaging voltage-gated sodium channels (VGSCs) that is more straightforward to synthesise than the known radiofluorinated phenoxyphenyl pyrazole carboxylic acid compounds. The compound of the present invention demonstrates specific uptake and retention in key tissues as well as good in vivo stability. Also provided by the present invention is a radiopharmaceutical composition comprising the radiofluorinated compound of the invention, precursor compounds and methods for the synthesis of said radiofluorinated compound, and methods for using said radiofluorinated compound.
- -
-
Page/Page column 22
(2013/09/26)
-
- Inhibitors of Protein Tyrosine Kinase Activity
-
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
- -
-
-
- OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
-
ABSTRACT The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by -Y1-A1- or -Y2-C(=O)- wherein Y1 is a group such as -C(=O)-, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
- -
-
Page/Page column 167
(2008/06/13)
-
- NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESI
-
The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and
- -
-
Page/Page column 42
(2008/06/13)
-
- AMIDES AND METHOD FOR PLANT DISEASE CONTROL WITH THE SAME
-
N-(α-cyanobenzyl)amide compounds represented by the formula (1): wherein R1 represents a hydrogen atom; a halogen atom; a C1-C6 alkyl group optionally substituted with a halogen atom or the like; or the like, R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group or the like, R3 represents a hydrogen atom or the like, R4 represents a C1-C4 alkyl group, a C3-C4 alkenyl group or the like, R5 represents a C1-C4 alkyl group, a C3-C4 alkenyl group, or the like, R6 represents a hydrogen atom or the like, R7 represents a hydrogen atom or the like, R8 represents a hydrogen atom or the like, R9 represents a hydrogen atom or the like, R10 represents a hydrogen atom or the like, R11 represents a hydrogen atom or the like, and R12 represents a hydrogen atom or the like, have excellent control activities against plant diseases.
- -
-
Page/Page column 73
(2010/11/08)
-
- Method for sulphonylating a hydroxylated organic compound
-
The invention concerns a method for sulphonylating a hydroxylated organic compound. The invention concerns in particular aliphatic hydroxylated compounds and more particularly those which comprise on their aliphatic chain, an electroattractive group. The
- -
-
-
- Mandelic acid derivatives and their use as throbin inhibitors
-
There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
- -
-
Page/Page column 29
(2008/06/13)
-
- NEW SALTS
-
There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n rep
- -
-
-
- IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION
-
According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen
- -
-
-
- MODIFIED RELEASE PHARMACEUTICAL FORMULATION
-
A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy
- -
-
-
- PHARMACEUTICAL COMBINATION
-
There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.
- -
-
-
- 2-Haloethylating Agents for Cancer Chemoterapy. 2-Haloethyl Sulfonates
-
Because certain (2-chloroethyl)triazenes and (2-haloethyl)nitrosoureas have high antineoplastic activity, 2-chloroethyl and 2-fluoroethyl sulfonates were prepared to try to develop additional types of 2-haloethylating agents.In this initial study, it was demonstrated that antineoplastic activity much superior to that of the prototype, 2-chloroethyl methanesulfonate, could be found among 2-chloroethyl sulfonates.Among a variety of 2-chloroethyl alkane- and arenesulfonates, several substituted methanesulfonates displayed significant activity agains P388 leukemia in mice; the chloromethanesulfonat e showed high activity (T/C = 218percent).None of the arenesulfonates were active in this test.
- Shealy, Y. Fulmer,Krauth, Charles A.,Struck, Robert F.,Montgomery, John A.
-
p. 1168 - 1173
(2007/10/02)
-